Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 6:18 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CLSD 1.31 +0.03(2.34%)
Will CLSD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLSD
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Other News for CLSD
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Buy Rating for Clearside Biomedical’s CLS-AX Based on Superior Efficacy and Market Adoption Potential
Clearside Biomedical management to meet with Oppenheimer
Clearside Biomedical’s CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target